Healthcare Industry News: drug-eluting stent
News Release - September 21, 2006
Cordis Corporation and Brivant Limited Sign Distribution Agreement for Three Interventional ProductsAgreement Expands Cordis' Portfolio of Innovative Products
MIAMI, Sept. 21 (HSMN NewsFeed) -- Cordis Corporation announced today that it has signed a definitive agreement whereby Cordis will be the worldwide distributor of Brivant's most advanced guidewires, which are products used to place catheters and drug-eluting stents in a patient's coronary system. The wires can also be used for products targeting the peripheral system.
"The addition of these three guidewires to our current line of innovative products adds depth to our cardiology and vascular portfolios," said Rick Anderson, Company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman, Cordis Corporation. "This agreement extends our commitment to physicians and the millions of people they treat with coronary and vascular diseases."
The three products covered under this agreement include a general-purpose guidewire, a guidewire targeted for highly stenosed lesions and a specialty J-tip guidewire used to navigate challenging anatomies. Cordis will market these guidewire products under an umbrella brand known as REGATTA(TM).
In recent months, Cordis has been strengthening its portfolio of catheters and balloons. Cordis recently announced availability in the United States, Canada and Europe of the STEER-IT(TM) Deflecting Tip Guidewire, designed to help physicians treat hard-to-reach blockages, and the launch an advanced percutaneous transluminal coronary angioplasty (PTCA) balloon catheter called the CRESCENDO(TM) PTCA Balloon Dilation Catheter in all countries except the U.S, Japan and Canada.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.